In a significant leadership announcement, global biopharmaceutical company Ipsen has revealed the appointment of Pierrick Lefranc as Executive Vice President of Technical Operations and a member of the Executive Leadership Team. This strategic move will take effect on April 1, 2026, marking a new chapter in the company's operational leadership.
Leadership Transition at Ipsen
Pierrick Lefranc will succeed Aidan Murphy, who has served as Executive Vice President of Technical Operations and member of the Executive Leadership Team. After an impressive 30-year tenure with Ipsen, Murphy will retire in March 2026, concluding a distinguished career marked by significant contributions to the company's manufacturing excellence.
Extensive Pharmaceutical Experience
Lefranc brings to his new role more than three decades of comprehensive experience within the pharmaceutical sector. His career has been characterized by leadership in manufacturing operations and the management of large-scale industrial projects, consistently demonstrating an ability to enhance productivity, improve quality standards, and ensure regulatory compliance across complex operations.
Since July 2019, Lefranc has held the position of Senior Vice President at Ipsen, where he has overseen global manufacturing activities, engineering functions, and enterprise excellence initiatives. His journey with the company began in 2013, and he was appointed Head of the Signes site in France in 2016, demonstrating his progressive leadership within the organization.
Reporting Structure and Location
In his new capacity, Pierrick Lefranc will be based in Paris and will report directly to David Loew, Chief Executive Officer of Ipsen. This direct reporting line underscores the strategic importance of the Technical Operations function within the company's leadership structure.
Executive Perspectives on the Appointment
David Loew, CEO of Ipsen, expressed his enthusiasm about the appointment, stating: "I am pleased to welcome Pierrick to the Executive Leadership Team, bringing with him decades of leadership and strategic transformation expertise gained both within Ipsen and across major pharmaceutical companies." Loew also acknowledged the departing executive, adding: "I would also like to extend my sincere appreciation for Aidan's commitment to Ipsen and wish him much success and happiness in his next chapter. Throughout his leadership roles, Aidan has built a first-class manufacturing team across the globe while driving transformation and excellence within Technical Operations, which has been recognized by several Shingo awards."
Pierrick Lefranc shared his perspective on the new role: "I'm thrilled to be joining the Executive Leadership Team and look forward to being an integral member of Ipsen's ongoing transformation. I would also like to thank Aidan for his leadership throughout the years and wish him all the best for his retirement."
About Ipsen
Ipsen operates as a global biopharmaceutical company with a focused mission to deliver transformative medicines to patients across three key therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company's research and development pipeline benefits from both internal innovation and external collaborations, supported by nearly a century of development experience.
The organization maintains global operational hubs in the United States, France, and the United Kingdom, with teams distributed across more than 40 countries worldwide. Through strategic partnerships and its extensive international presence, Ipsen facilitates the delivery of medicines to patients in over 100 countries, demonstrating its global reach and impact in the pharmaceutical sector.
Ipsen is publicly listed on the Euronext Paris exchange under the symbol IPN and participates in the U.S. market through a Sponsored Level I American Depositary Receipt program with the ticker IPSEY. This dual listing structure reflects the company's international investor base and global business operations.
